PCV salvage chemotherapy for recurrent primary CNS lymphoma

Neurology. 2000 Apr 25;54(8):1707-8. doi: 10.1212/wnl.54.8.1707.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Central Nervous System Neoplasms / drug therapy*
  • Central Nervous System Neoplasms / mortality
  • Female
  • Humans
  • Lomustine / adverse effects
  • Lomustine / therapeutic use
  • Lymphoma / drug therapy*
  • Lymphoma / mortality
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Procarbazine / adverse effects
  • Procarbazine / therapeutic use
  • Remission Induction
  • Salvage Therapy*
  • Survival Rate
  • Treatment Outcome
  • Vincristine / adverse effects
  • Vincristine / therapeutic use

Substances

  • Procarbazine
  • Vincristine
  • Lomustine

Supplementary concepts

  • PCV protocol